Navigation Links
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
Date:11/19/2007

AMSTERDAM, November 19 /PRNewswire/ -- Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete at the end of this year. Kiadis Pharma anticipates applying for and starting a phase III study in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites participating in the ongoing phase II trial were left without treatment alternatives following the announcement of the enrolment closure. The interest these physicians show in using our product for new patients is very encouraging and we are very pleased that we can support them by providing Rhitol through special provisions, until the start of the phase III clinical trial."

The physicians interested in enabling new patients to receive treatment with Rhitol will obtain regulatory authorization from the appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid refractory Graft versus Host Disease (GvHD) who have exhausted other treatment options. Chronic GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. The immune cells from the donor graft cause GvHD by attacking the patient's tissues and organs. There are two forms of GvHD: acute GvHD appears within 100 days after transplantation and chronic GvHD begins anytime after that period. Immune-suppressant drugs, such as steroids, are generally used to treat chronic GvHD. The disease can become a life-threatening condition when standard treatment cannot control its progression as the patient either does not respond to steroid treatment or develops severe side effects due to their use. Extensive chronic GvHD affects multiple organs and tissues and results in diminished quality of lif
'/>"/>

SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...-USNewswire/ -- During a memorial service in the ... remembered Lieutenant Governor Catherine Baker Kn... public service, and a tireless advocate for the p...man elected lieutenant governor, Catherine was a n...ndell. "Her family and her faith were driving forc...
(Date:11/21/2008)...irstCall/ -- The Providence Service,Corporation (...ris, the Company,s,Chief Operating Officer, has b.... Mr. Norris, appointment fills the vacancy left ...er and returns the board to six members. Mr.,Nor..., Mr. Norris, age 41, has been with Provide...
(Date:11/21/2008)...t future antibiotic resistance from widespread use...-- People with moderate to severe chronic obstruct... the frequency of exacerbations through a regular,...s. , The study, published in the first issue f...y and Critical Care Medicine , found that twice-da...
(Date:11/21/2008)...l technique to combat cancer, study says, , ...an researchers have discovered that some cancer ce... this might lead to new treatments that starve and..., all cells in the body need to produce energy. Th...hat requires oxygen. Compared with normal cells, t...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:New Approach Keeps Tumor Cells From Refueling 2
...is a classic example of “the blame game”. A retire...a Las Vegas gambling spree. This is news yes but t...on a drug prescribed to treat his Parkinson's dise...ney back. The name of this great man is Max Wells...
...k force constituted by Haryana Agricultural Univer...fy bird flu infection if any in the state. // No e... the taskforce that visited various districts of t...rce found the birds healthy with a routine and nor...
...s in a Surname? There’s a lot you can decipher fro...milar surnames. Gender Bias, if you ask me! Or bla... to a Man; researchers, have now unearthed a myste...tree to common Surnames. DNA of 150 pairs of men w...
...nts, most often the elderly are wanting in good he...he NHS have been asked to give better care, especi...ishment.// The National Institute for Health and ...ed initial screening of all out-patients, prior to...
Other Medicine News:
(Date:11/20/2008)...Nov. 20 Milk. It does a body good....y thought. After years of,research, scientists at...in,cow,s milk that stimulate the body,s own produ...ltimedia News Release, go to:, http://www.prnewswi...developing new cancer therapies, the chief scienti...
(Date:11/20/2008)...ov. 20 Duska Therapeutic...day that it has submitted its,pivotal Phase 3 ATP...cial,Protocol Assessment (SPA) procedure with the... Subject to securing an agreement with the FDA, D...ouble-blind, placebo-controlled and randomized Pha...
(Date:11/20/2008)...PRNewswire/ -- Clinical data from a prospective,r...th Symposium shows DVT,treatment with the Trellis...lar, Inc. (Santa Clara, CA) successfully breaks up...tes. , This technique, called isolated phar...more quickly and safely than current catheter-dire...
(Date:11/20/2008)... November 20 The Scandinavian-base...nounced results of studies on its,lead antimicrob...ngton, DC,the studies showed that the novel lyti... effect, significantly better towards killing Stap... marketed gold standard drugs. In,addition to thi...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 29761 1MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 29761 2MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 29761 3Cystic Fibrosis Foundation Establishes Landmark Patient Assistance Foundation 29757 1Cystic Fibrosis Foundation Establishes Landmark Patient Assistance Foundation 29757 2Recognized Dermatology Expert Dr Zoe Draelos Joins Histogen Scientific Advisory Board 9185 1Recognized Dermatology Expert Dr Zoe Draelos Joins Histogen Scientific Advisory Board 9185 2Recognized Dermatology Expert Dr Zoe Draelos Joins Histogen Scientific Advisory Board 9185 3Voler Expands Medical Device Design Capabilities 9181 1Voler Expands Medical Device Design Capabilities 9181 2Voler Expands Medical Device Design Capabilities 9181 3
For the determination of urea nitrogen in human serum.
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic, lag phase of less than 120 seconds, followed by linear phase of at least 240 seconds. Wavelength: 340 nm. Lin
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C.
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl
Medicine Products: